Filing Flows

Filing Flows › Companies › Kyntra Bio › Cash flow

Kyntra Bio cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$4.0M in Q2 2026 · −$38.1M over twelve months

Operating cash flow−$4.0M
Free cash flow−$4.0M
Cash / net income-0.3×

Analysis

In Q2 2026, Kyntra Bio generated −$4.0M of operating cash flow. That is $16.7M less than in Q2 2025 ($12.7M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$38.1M; the largest uses were other financing ($85.9M), operating cash flow ($38.1M), taxes on employees’ shares ($32K); besides operations, cash came from other investing ($56.1M); the cash balance fell by $69.2M.

Operating cash flow was −$4.0M against net income of $12.0M — -0.3× profit, less cash than reported earnings, worth checking against working capital. The largest differences: accrued liabilities +$6.5M, receivables +$4.7M, payables +$2.4M.

Free cash flow

Kyntra Bio: free cash flow by quarterKyntra Bio: free cash flow by quarter−$8.5MQ3 2024−$30.6MQ4 2024$2.7MQ1 2025$12.7MQ2 2025−$1.9MQ3 2025−$18.3MQ4 2025−$13.9MQ1 2026−$4.0MQ2 2026
Operating cash flow less capital spending.
Kyntra Bio: operating cash flow against capital spendingKyntra Bio: operating cash flow against capital spendingOperating cash flowCapital spending−$8.4M$82KQ3 2024−$30.5M$141KQ4 2024$2.7M$16KQ1 2025$12.7M$13KQ2 2025−$1.8M$9KQ3 2025−$18.3M$0Q4 2025−$13.9M$0Q1 2026−$4.0M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$4.0M, Capital spending $0.

Capital allocation, year by year

Kyntra Bio: where the cash came from (up) and went (down), by fiscal yearKyntra Bio: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$82.2MFY2021: Shares issued $12.7MFY2021: Capital spending −$5.2M$12.7MFY2021FY2022: Operating cash flow −$146MFY2022: Shares issued $4.2MFY2022: Asset sales $6KFY2022: Capital spending −$3.7M$4.2MFY2022FY2023: Operating cash flow −$315MFY2023: Net borrowing $71.3MFY2023: Shares issued $3.7MFY2023: Capital spending −$2.5M$75.1MFY2023FY2024: Operating cash flow −$138MFY2024: Shares issued $139KFY2024: Asset sales $1.0MFY2024: Capital spending −$266K$1.2MFY2024FY2025: Operating cash flow −$4.8MFY2025: Net borrowing −$75.0MFY2025: Asset sales $96.6MFY2025: Capital spending −$38K$96.6MFY2025
Over these 5 years operating cash flow totalled −$686M; the largest uses were operating cash flow ($686M) and net borrowing ($75.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$91.3M
Debt$75.0M
Net cash$16.3M
Cash runway2.4 years

Kyntra Bio is burning cash: its operations consume cash, a free cash flow of −$38.1M a year at the current rate against $91.3M of cash and investments: a runway of about 2.4 years before any new financing.

Where the cash came from and went

Kyntra Bio: sources (+) and uses (−) of cash, Q2 2026Kyntra Bio: sources (+) and uses (−) of cash, Q2 2026Other investing$17.7MCash drawn (+) / kept (−)−$13.6MOperating cash flow−$4.0MExchange rates−$30KTaxes on employees’ shares−$5K
Kyntra Bio: sources (+) and uses (−) of cash, TTM to Q2 2026Kyntra Bio: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing−$85.9MCash drawn (+) / kept (−)$69.2MOther investing$56.1MOperating cash flow−$38.1MExchange rates−$1.3MTaxes on employees’ shares−$32KCapital spending−$9K

From profit to cash

Kyntra Bio: net income to operating cash flow, Q2 2026Kyntra Bio: net income to operating cash flow, Q2 2026Net income$12.0MStock-based pay$984KReceivables$4.7MPayables$2.4MAccrued liabilities$6.5MDeferred revenue−$1.7MPrepaid and other assets−$83KOperating cash flow−$4.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 202663789745
Q4 20251212591462-192
Q2 20251037579506-5740
Q1 20251011272205-1068

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$4.0M——−$13.6M−$4.0M
Q1 2026−$13.9M——$10.9M−$13.9M
Q4 2025−$18.3M——$70.1M−$18.3M
Q3 2025−$1.8M−$9K—$1.9M−$1.9M
Q2 2025$12.7M−$13K—−$13.6M$12.7M
Q1 2025$2.7M−$16K—−$4.0M$2.7M
Q4 2024−$30.5M−$141K$23K$28.8M−$30.6M
Q3 2024−$8.4M−$82K—$9.7M−$8.5M

Kyntra Bio: income statement and cash flow

Kyntra Bio, Q1 2026: revenue $3.7M (+36% year over year), operating margin -369.7%. The chart follows the revenue to costs, profit and cash.

Kyntra Bio: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.